UGN-104

DRUG2 trials

Sponsors

Urogen Pharma Ltd., UroGen Pharma Ltd.

Conditions

Low-grade Upper Tract Urothelial CancerUpper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma

Phase 3

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

RecruitingNCT06774131

UroGen Pharma Ltd.Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

Start: 2025-08-06End: 2028-03-01Target: 70Updated: 2026-09-03

Protocol Title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

RecruitingCTIS2024-519343-15-00

Urogen Pharma Ltd.Low-grade Upper Tract Urothelial Cancer

Start: 2025-10-08Target: 59Updated: 2026-01-27